Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
All Participants	STARTED	Ruxolitinib	155
All Participants	STARTED	Placebo	154
All Participants	Safety Population	Ruxolitinib	155
All Participants	Safety Population	Placebo	151
All Participants	COMPLETED	Ruxolitinib	134
All Participants	COMPLETED	Placebo	114
All Participants	NOT COMPLETED	Ruxolitinib	21
All Participants	NOT COMPLETED	Placebo	40
Patients Who Crossed Over to Ruxolitinib	STARTED	Ruxolitinib	0
Patients Who Crossed Over to Ruxolitinib	STARTED	Placebo	111
Patients Who Crossed Over to Ruxolitinib	COMPLETED	Ruxolitinib	0
Patients Who Crossed Over to Ruxolitinib	COMPLETED	Placebo	57
Patients Who Crossed Over to Ruxolitinib	NOT COMPLETED	Ruxolitinib	0
Patients Who Crossed Over to Ruxolitinib	NOT COMPLETED	Placebo	54

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00952289/flow